BofA analyst Greg Harrison upgraded Stoke Therapeutics to Neutral from Underperform with a price target of $12, up from $9. The firm’s confidence is Stoke’s TANGO platform has increased following trial updates on STK-001 in Dravet syndrome and CTA acceptance of STK-002 in ADOA, the analyst tells investors. BofA has raised its view of the odds of success in Dravet to 25% from 20%, it noted.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on STOK:
- Stoke Therapeutics assumed with a Buy at Canaccord
- Stoke Therapeutics receives authorization to initiate STK-002 study in UK
- Stoke: FDA allows higher single dose of STK-001 in 1/2a MONARCH study
- Stoke Therapeutics price target lowered to $25 from $33 at Wedbush
- Stoke Therapeutics reports Q4 net loss $25.7M vs. $24.4M last year
